InvestorsHub Logo
Followers 4
Posts 1198
Boards Moderated 0
Alias Born 10/03/2015

Re: NY1972 post# 162

Sunday, 04/03/2016 11:00:00 AM

Sunday, April 03, 2016 11:00:00 AM

Post# of 977
Cabozantinib is a potent targeted therapy that inhibits MET

Partial bone scan resolution in 4 of 10 evaluable patients, no CD47 status

http://www.exelixis.com/sites/default/files/Winer_MBC_ASCO%202012_FINAL_poster_535.pdf